- Science
- Clinical Trials
- Guide to Clinical Trials Your participation makes a difference
- Clinical Trials in Children Designed to improve kids' health
- Data and Results Sharing our Results
- Integrity and Transparency Building Trust
- Diversity Equity and Representation
- Plain Language Study Results Trial Result Summaries
- Expanded Access & Compassionate Use Possible Treatment Options
- Find a Trial
- Areas of Focus
- Rare Disease Smaller populations but big impact
- Internal Medicine Extending lifespans worldwide
- Inflammation & Immunology Treatment at the molecular level
- Vaccines Preventing the spread of infections
- Oncology The science of optimism
- Anti Infectives Combatting an evolving risk
- Areas of Innovation
- Gene Therapy Breakthroughs become treatments
- Medicinal Sciences The next generation of science
- Precision Medicine Developing tailored medicines
- Maternal Immunization Protecting newborns at the start
- mRNA Technology Unleashing the next wave of scientific innovations
- Diseases & Conditions
- Coronavirus Resources
- Product Pipeline
- Research Sites
- Clinical Trials
- Products
- How Drugs are Made
- Branded vs. Generic Learn the difference
- Biologics & Biosimilars Cures found in nature
- Commitment to Quality Maintaining the highest standards
- Global Supply Strategic manufacturing locations
- Manufacturing Sites Where medicine is made in the U.S.
- Medicine Safety
- Health Literacy Learning to be well
- Treatment Choices Learning about treatment decisions
- Partnering With Patients Helping others by reporting side effects
- Tips for Patients Preventing medication errors
- Reporting Adverse Events
- Counterfeiting Preventing medication errors
- Safety Data Sheets
- Product List
- Product Contacts
- PfizerPro for Professionals
- Patient Assistance Programs
- Distributors
- How Drugs are Made
- Stories
- Newsroom
- About
- People
- Executives Our senior-most leadership
- Board Members The people steering our company
- Scientists Our experts making discoveries
- Patient Stories Our patients
- Colleague Stories Our colleagues
- Responsibility
- Ethics & Compliance Each of us is responsible
- Diversity, Equity, and Inclusion Everyone has something to offer
- EHS Governance
- Environmental Sustainability Our responsiblity to the environment
- Global Impact Meeting urgent needs worldwide
- Health & Safety
- Human Rights Furthering dignity and worth
- Intellectual Property The benefits of fair competition
- Patient Advocacy & Engagement Putting Patients First
- Misinformation
- Programs & Policies
- Grants Support for independent research
- Political Partnership Supporting like-minded organizations
- Working with Healthcare Professionals Collaboration to improve lives
- Prescription Value & Pricing How to lower patient costs
- Privacy Principles Commitment to personal data privacy
- Ready for Cures Improving Access to Medicines
- Transparency in Grants Committed to Disclosure
- Investors
- Investors Overview Information for stockholders
- Why Invest Why to join us in our mission
- Events & Presentations Calendar of upcoming events
- Financial Reports Quarterly reports and more
- Investor News Announcements about our performance
- Stock Information Charts and data
- Shareholder Services Information on stock transactions
- Corporate Governance
- Corporate Governance Overview Gaining insight into our performance
- Board Committees & Charters Defining the corporate structure
- The Pfizer Board Policies Ensuring ethical leadership
- Corporate Governance FAQs Learn more about our approach
- Contact Our Directors Email any of our Directors
- Purpose
- History
- Careers
- Partners
- People
Pfizer Ventures: How We Work
We actively support our current portfolio companies throughout their growth cycles contributing strategic guidance in addition to capital as well as access to Pfizer expertise, when appropriate.
- With a $600M capital commitment for investment, Pfizer Ventures backs private companies at all stages of development.
- We have a strong focus on early-stage opportunities. But other investments, including start-ups and spinouts, are also considered in scope.
- While primarily U.S. focused, international investments may represent up to 20 percent of the portfolio.
- We can lead or join a syndicate of investors and will seek board representation commensurate with our investment.
- Our investments are focused on potentially transformative therapeutics, with an emphasis in our core therapeutic areas: Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, and Vaccines.
- We also consider platform technologies, diagnostics, drug delivery, pharmaceutical services, and other technologies that have the potential to transform drug discovery and development
- Pfizer Ventures is an active investor, working with management to develop product strategy and shareholder value.
- We bring a pharmaceutical perspective and have the potential to utilize our internal networks and expertise.
- We have a streamlined approval process for investment decisions.
- All investments have the potential for a business relationship with Pfizer.
Key Points
- Focus
- Emphasis primarily on therapeutics (80%)
- Platforms, tools, and technologies with potential to transform drug discovery and development are also considered (20%)
- Geography
- U.S. focused primarily
- Approximately 20 percent of investments may be outside the U.S
- Investment Type
- Direct investing in private companies
- All stages possible, with focus on early stage
- Returns
- Strategic and financial
- Measured over long term
- Funding
- $600M current capital commitment from Pfizer AUM $1.3B
- Up to $15M in first investment; reserved allocation for follow-on investments
- Syndication
- Investing as member of a syndicate
- Syndicate member must be located near company
- Collaboration
- Potential for business relationship with Pfizer considered in investment criteria
- Can be transacted in parallel with investment or explored in the future
- Influence in Development
- Contribute capital and industry experience to help guide development and company growth
- Scientific advisory board participation when appropriate
- Control
- Minority ownership positions
- Board seats where appropriate
- Deal Structure
- Traditional VC investment
- Product rights not required
